A Phase 2 interventional study of LSD and Active placebo in Alcohol Use Disorder (AUD), sponsored by Felix Mueller. Recruiting at 2 sites in Switzerland. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Felix Mueller · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Alcoholism with a site in Switzerland — 4 open to participants now, 4 under way, none of them phase 3. Alcoholism · Switzerland.
Among the 12 studies in Alcoholism with a site in Switzerland, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 7th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →4 of the 12 studies in Alcoholism with a site in Switzerland are open now. Recruiting first, the newest first:
Dr. med. Marcus Herdener · Sites in Switzerland
Ages 18–65
University of Bern · Sites in Switzerland
Ages 18–80
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–80
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 25 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 128 is above the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 57 across the 10 interventional studies, 188 across the 2 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 7 most frequent:
Felix Mueller is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Felix Mueller has 1 study filed under Alcoholism — fewer than ten, so there is no comparison to draw.
2 of the studies in Alcoholism with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06969937Dr. med. Marcus HerdenerKetamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder | 2026-12 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Alcoholism with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lysergic acid diethylamide (LSD) was investigated in numerous clinical trials during the 1950s and 1960s. Specifically, the use of LSD in the treatment of AUD was investigated extensively. A pooled analysis of six historical clinical trials demonstrated that a single dose of LSD significantly reduced alcohol use at three and six months after LSD administration. However, these trials are limited by several factors, including the use of diagnostic standards that are no longer up to date, single, high-dose treatment regimes, missing biological assessment for alcohol use, and no consequent assessment of blinding.
This trial will assess the efficacy and safety of two moderate to high doses of LSD to decrease alcohol consumption in patients with AUD. The trial has a double-blind, active placebo-controlled, randomized, parallel design and will be conducted in specialized treatment centers for addictive disorders in Switzerland. The study will include 128 patients who have undergone detoxification. Participants will be allocated to one of the two intervention arms (1:1 allocation). Each arm comprises nine study visits (no drug administration) and two study days (involving LSD administration) within 30 weeks. Patients allocated to the control intervention (active placebo group) will receive 10 µg LSD on the first study day and either 10 or 20 µg LSD on the second study day. Patients allocated to the treatment intervention will receive 150 µg LSD on the first study day and either 150 µg or 250 µg LSD on the second study day. The dose will be retained or increased depending on the patient's individual response on the first study day. Participants in the control intervention will be offered to attend an open-label LSD session (150 µg) at week 31. The open-label phase will comprise three additional visits. This trial will further compare the effectiveness of LSD-assisted therapy in both group and individual therapeutic settings. To this end, participants in both drug conditions will be randomly assigned to group or individual settings.
The primary outcome is the mean of percent heavy drinking days after administration of two doses of LSD during the 12 weeks following the second administration. Secondary objectives: The second aim of this study is to explore long-term changes in the cortical thickness, white matter microstructure, resting state functional connectivity (rs-FC) and cerebral blood flow (CBF) of regions associated with addiction pathophysiology. Furthermore, we will assess alterations in depressive symptoms, anxiety, and persisting effects of LSD. We will also assess biological markers of alcohol use and several predictors for treatment-response (genetics, personality traits, blinding, expectancy, and quality of acute drug effects). Lastly, we will compare LSD treatment within a group setting with treatment within an individual setting.
Patients will be followed up six months after the second administration in the double-blind phase. At this time point, a predefined subset of the questionnaires used in the main study will be administered (TLFB, SIP-2R, OCDS, drinking goals, self-efficacy, BSCL, BDI, and BAI; see below).
During the open-label phase, patients will be assessed one month after administration. This assessment will include a subset of questionnaires (TLFB, OCDS, BSCL, BAI, BDI, CHIME, WHOQOL-BREF, drinking goals, self-efficacy, and WVQ; see below). In addition, the open-label phase will include assessments of acute drug effects, expectancy, and adverse events (see below).
Key inclusion criteria:
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in the treatment arm will receive 150 μg LSD (first session) and 150 or 250 μg LSD (second session).
Drug: LSD
Subjects in the control arm will receive 10 µg LSD at the first session and 10 or 20 µg LSD at the second session.
Drug: Active placebo
Moderate to high dose LSD
Low dose LSD
Percent heavy drinking days
The primary outcome is the mean percentage of heavy drinking days after administration of two doses of LSD assessed with the alcohol timeline follow-back (TLFB) questionnaire compared between treatment groups
Time frame: Period of three months after the second administration
Cortical thickness measured with MRI
Changes in the cortical thickness of the ACC, PCC, and PFC
Time frame: One month after the first administration, one month after second administration
The volume of the striatum measured with MRI
Changes in the volume of the striatum
Time frame: One month after the first administration, one month after second administration
White matter microstructure measured with MRI
Changes in white matter microstructure in the cingulum bundle and the PFC-striatal connection pathway
Time frame: One month after the first administration, one month after second administration
Days to first heavy drinking day
Days to first heavy drinking day after the first and second administration assessed with TLFB
Time frame: One month after the first administration, one, two, and three months after the second administration
Days to first drinking day
Days to first drinking day assessed after the first and second administration assessed with TLFB
Time frame: One month after the first administration, one, two, and three months after the second administration
Percent days abstinent
Percent days abstinent after the first and second administration assessed with TLFB
Time frame: One month after the first administration, one, two, and three months after the second administration
Drinks per drinking day
Drinks per drinking day after the first and second administration assessed with TLFB
Time frame: One month after the first administration, one, two, and three months after the second administration
Percent heavy drinking days
Percent heavy drinking days assessed with TLFB
Time frame: One month after the first administration
Adverse consequences of alcohol use
Adverse consequences of alcohol use assessed with the Short Inventory of Problems (SIP-2R) questionnaire
Time frame: Three months after the second administration
Craving
Craving assessed with the Obsessive Compulsive Drinking Scale (OCDS)
Time frame: Three weeks after the first administration, three weeks, two and three months after the second administration
Ethyl glucuronide
Ethyl glucuronide (EtG) in hair
Time frame: Three months after the second administration
Phosphatidylethanol
Phosphatidylethanol (PEth) in blood
Time frame: At each administration and three months after the second administration
Perceived quality of life across multiple domains
Quality of life assessed with the World Health Organization Quality of Life Scale (WHOQOL-bref). Domain scores are transformed to a 0-100 scale. Higher scores indicate better quality of life.
Time frame: One and two months after the second administration
Depression
Beck Depression Inventory (BDI-II). Total score range: 0-63. Higher scores indicate more severe depressive symptoms
Time frame: Three weeks after the first administration, one and three months after the second administration
Anxiety
Beck Anxiety Inventory (BAI). Total score range: 0-63. Higher scores indicate more severe anxiety symptoms (worse outcome)
Time frame: Three weeks after the first administration, one and three months after the second administration
Various somatic and psychological symptoms
Various somatic and psychological symptoms assessed with the Brief Symptom Checklist (BSCL). The BSCL contains 53 items rated on a 5-point Likert scale from 0 ("not at all") to 4 ("extremely"), covering nine symptom dimensions (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism). The Global Severity Index (GSI) is calculated as the mean across all 53 items and ranges from 0 to 4. Higher scores indicate greater symptom burden (worse outcome).
Time frame: Three weeks after the first administration, one and three months after the second administration
World view
World views will be assessed using the World View Questionnaire (WVQ)
Time frame: Three weeks after the first administration, three weeks after the second administration
Persisting effects
Persisting effects of LSD assessed with the Persisting Effects Questionnaire (PEQ)
Time frame: Three months after the second administration
Mindfulness
Mindfulness will be assessed using the Comprehensive Inventory of Mindfulness Experience (CHIME)
Time frame: Three weeks after the first administration, three weeks after the second administration, two months after the second administration
Acute effects of LSD
Acute effects assessed with the 5 Dimensions of Altered States of Consciousness (5D-ASC). Visual analog scales range from 0 to 100. Higher scores indicate more intense effects on the respective dimension.
Time frame: The day after the first and the day after the second administration
Acute effects of LSD
Acute effects assessed with the Mystical Experience Questionnaire (MEQ30). Each item is rated on 0 to 5, grouped into four subscales. Higher scores indicate more intense effects on the respective dimension.
Time frame: The day after the first and the day after the second administration
Acute effects of LSD
Acute effects assessed with the General Change Mechanisms Questionnaire (GCMQ)
Time frame: The day after the first and the day after the second administration
Acute effects of LSD
Acute effects assessed with the Phenomenological-Autobiographical-Existential Psychedelic Scale extended (PAE-PS-ext)
Time frame: The day after the first and the day after the second administration
Blinding
Blinding will be assessed directly after session 1 with a self-developed questionnaire that includes participants' guesses of their group assignment and their degree of certainty, rated on a visual analogue scale.
Time frame: In the evening after the first administration
Expectancy
Expectancy will be assessed with the Credibility / Expectancy Questionnaire (CEQ). Therapists' expectancy will also be assessed
Time frame: Two weeks before the first administration
Self-efficacy
Self-efficacy will be assessed using a visual analogue scale
Time frame: Three weeks after the first administration, three weeks after the second administration, two and three months after the second administration
Drinking goals
Drinking goals will be assessed using pre-defined response options
Time frame: Three weeks after the first administration, three weeks after the second administration, two and three months after the second administration
Safety: Adverse events
Adverse events will be documented at each visit and each session.
Time frame: Week 0 to week 18
Qualitative Interview
Qualitative interview regarding subjective experiences of acute drug effects, benefits, possible negative effects, as well as the subjective concept of the potential psychological mechanisms
Time frame: Three months after the second administration
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Oct 2028, 33 months after the start.
Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 33 months is close to that.
Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lysergic Acid Diethylamide
Felix Mueller